Latest news with #CrodaInternational
Yahoo
16 hours ago
- Business
- Yahoo
Binder Excipients Market Research Business Report 2025-2030: Rising Demand for Solid Dosage Forms Spurs Growth, Increasing Focus on Patient-Centric Drug Formulations Expands Opportunities
The global Binder Excipients market, valued at US$2.0 Billion in 2024, is set to reach US$2.7 Billion by 2030 with a CAGR of 5.3%. Key drivers include rising demand for solid dosage forms and advancements in pharmaceutical technology. Notable trends are the shift towards natural excipients and multifunctional products. The report details market forecasts, regional growth, and major players like Asymchem Laboratories and Croda International. Explore in-depth insights for strategic decisions in the evolving binder excipients landscape. Binder Excipients Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Binder Excipients - Global Strategic Business Report" report has been added to global market for Binder Excipients was valued at US$2.0 Billion in 2024 and is projected to reach US$2.7 Billion by 2030, growing at a CAGR of 5.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Binder Excipients market. Binder excipients are essential components in pharmaceutical formulations, playing a crucial role in the manufacturing of solid dosage forms such as tablets and capsules. These substances are responsible for binding the various ingredients in a formulation together, ensuring that the final product is cohesive and stable. Without binders, the active pharmaceutical ingredients (APIs) and other excipients might not combine effectively, leading to issues with tablet integrity, dissolution, and Factors Are Driving the Growth of the Binder Excipients Market?The growth in the binder excipients market is driven by several factors, reflecting the changing dynamics of pharmaceutical manufacturing and consumer demand. One of the primary drivers is the increasing demand for solid dosage forms, such as tablets and capsules, which remain the most popular and convenient forms of medication delivery. This demand is further amplified by the rise in chronic diseases and the need for effective, long-term treatments that rely heavily on well-formulated solid dosage drugs. Another significant factor is the advancement in pharmaceutical technology, particularly in direct compression and high-speed tablet manufacturing, which has created a need for binders with superior compressibility and flow properties. Additionally, the growing focus on patient-centric formulations, including orally disintegrating tablets (ODTs) and pediatric formulations, is driving the demand for specialized binder excipients that can meet specific performance criteria. The shift towards natural and clean-label products is also influencing the market, with consumers and regulators alike pushing for more sustainable and biocompatible excipients. Finally, the expanding pharmaceutical production in emerging markets, driven by the rising healthcare needs and increasing access to medications, is contributing to the growth of the binder excipients market as manufacturers seek reliable and efficient binders to support large-scale production. What Are the Emerging Trends in the Binder Excipients Market?The binder excipients market is witnessing several emerging trends driven by the evolving needs of the pharmaceutical industry and changes in regulatory landscapes. One significant trend is the shift towards natural and sustainable binder excipients, as both consumers and manufacturers increasingly prioritize eco-friendly and renewable sources. Natural binders, derived from plant-based materials such as alginates, gums, and starches, are gaining popularity due to their biocompatibility, lower environmental impact, and the growing demand for clean-label products. Another trend is the increasing use of co-processed excipients, where two or more excipients are combined at a sub-particle level to create a single, multifunctional product. This approach not only enhances the functionality of the binder but also simplifies the formulation process, leading to better product consistency and performance. Regulatory requirements are also shaping the market, with stricter guidelines pushing for higher levels of excipient quality, safety, and traceability. This has led to a greater emphasis on excipient characterization, the adoption of quality-by-design (QbD) principles, and the use of advanced analytical techniques to ensure compliance and reliability in pharmaceutical production. These trends indicate a dynamic market that is continuously adapting to meet the demands of a rapidly changing pharmaceutical landscape. How Are Technological Advancements Shaping the Future of Binder Excipients?Technological advancements are driving significant innovations in the development and application of binder excipients, with a growing emphasis on enhancing performance and meeting specific formulation challenges. One of the most notable trends is the development of multifunctional excipients, which combine binding properties with other functional attributes such as disintegration, lubrication, and controlled release. This innovation simplifies the formulation process, reduces the number of excipients needed, and improves the efficiency of manufacturing. Additionally, the rise of direct compression technology has led to the demand for binders that perform well without the need for wet granulation, a traditionally complex and time-consuming process. This has spurred the development of binders with superior compressibility and flow characteristics, enabling faster and more cost-effective production of tablets. Moreover, the increasing focus on personalized medicine and the production of small-batch, high-potency drugs has necessitated the creation of binders that can support the precise formulation of low-dose medications. As technology continues to evolve, it is expected that binder excipients will become even more specialized, offering tailored solutions to meet the diverse needs of modern pharmaceutical Scope Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Asymchem Laboratories (Tianjin), Colorcon, Inc., Croda International Plc, Fuji Chemical Industry Co., Ltd., Ingredion, Inc. and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Cellulosics segment, which is expected to reach US$1.0 Billion by 2030 with a CAGR of a 5.7%. The Lactose-Based Binder Excipients segment is also set to grow at 5.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $538.4 Million in 2024, and China, forecasted to grow at an impressive 5.1% CAGR to reach $421.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments Type (Cellulosics, Lactose-Based Binder Excipients, Polyol Excipients, Povidone-Based Binder Excipients, Starch & Polysaccharides-Based Binder Excipients, Other Types) Application (Tablets & Capsules, Solution-Based) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 194 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2 Billion Forecasted Market Value (USD) by 2030 $2.7 Billion Compound Annual Growth Rate 5.3% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Binder Excipients - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Increasing Prevalence of Chronic Diseases Drives Adoption of Binder Excipients in Long-Term Medications Rising Demand for Solid Dosage Forms Spurs Growth in Binder Excipients Market Increasing Focus on Patient-Centric Drug Formulations Expands Addressable Market Opportunity Shift towards Multifunctional Excipients Strengthens Business Case for Advanced Binder Solutions Growing Trend of Personalized Medicine Generates Demand for Customized Binder Excipients Sustainability Concerns Throw the Spotlight on Bio-Based and Eco-Friendly Binder Excipients Innovation in Material Science Spurs Growth in High-Performance Binder Excipients Increasing Use of Co-Processed Excipients Expands Market for Binder Excipients Consumer Preference for Low-Dose and High-Potency Drugs Propels Need for Specialized Binders Advances in Biopharmaceuticals Sustain Growth in Demand for Innovative Binder Excipients FOCUS ON SELECT PLAYERS:Some of the 42 companies featured in this report Asymchem Laboratories (Tianjin) Colorcon, Inc. Croda International Plc Fuji Chemical Industry Co., Ltd. Ingredion, Inc. Maple Biotech Pvt., Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Binder Excipients Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Reuters
23-04-2025
- Business
- Reuters
UK stocks rise after Trump backtracks on remarks over Fed
April 23 (Reuters) - UK shares climbed on Wednesday, led by the gains in chemical companies and metal mining firms, while markets also found relief in U.S. President Donald Trump's reversal of his threats to fire Federal Reserve Chair Jerome Powell. As of 1045 GMT, the blue-chip FTSE 100 index (.FTSE), opens new tab was up 1.3% and the midcap index (.FTMC), opens new tab gained 1.2%. Hopes for trade negotiations between the U.S. and China, which have been locked in an escalating tit-for-tat tariff war, also helped lift sentiment after Trump expressed optimism that a trade deal with the country could "substantially" lower tariffs on Chinese goods. The chemicals index (.FTNMX552010), opens new tab led the gains with Croda International (CRDA.L), opens new tab jumping 10.7% after the company reported 8% growth in first quarter group sales. Croda also topped the FTSE 100 index. BP (BP.L), opens new tab climbed 5% after activist investor Elliott increased its stake in the oil major to just over 5%. An index of UK's energy companies (.FTNMX601010), opens new tab rose 3.6% after oil prices climbed more than 1% on a fresh round of U.S. sanctions on Iran and a drop in U.S. crude stocks. Industrial metal miners (.FTNMX551020), opens new tab were also up 4.5% in the day as copper prices in London hit a near three-week high. Babcock (BAB.L), opens new tab rose 2% after the engineering firm said it expects, opens new tab fiscal 2025 operating profit to jump 17%. On the data front, British businesses faced a sharp downturn in April as activity contracted to its lowest level since November 2022, the S&P Global's Composite PMI showed on Wednesday. The sharp drop in business activity is likely to further cement expectations that the Bank of England will cut interest rates next month. Reckitt (RKT.L), opens new tab was among the worst performers on the blue-chip index as the maker of Dettol and Lysol cleaning products missed first-quarter like-for-like net sales growth estimates. Its shares dropped 5.9%. On the midcap index, Hochschild Mining (HOCM.L), opens new tab tumbled 16.9% and was set for the biggest loss in more than three years after the precious metal miner missed first quarter production esimates.
Daily Mail
23-04-2025
- Business
- Daily Mail
Footsie jumps and gold slumps as Trump eases pressure on Fed boss
The FTSE 100 extended gains on Wednesday as global stocks were lifted by the potential easing of US-China trade tensions. London's blue chip index was 1.3 per cent higher at 8,436.04 by 11am, taking its winning streak to eight consecutive sessions. US stocks were also back in vogue as President Donald Trump appeared to rule out plans to fire the Federal Reserve's chairman Jerome Powell. Investors dumped US assets on Monday after Trump sparked fears over the independence of the country's central bank, driving gold to a fresh record high. Trump's latest climbdown has pushed gold around 5 per cent lower for the day, while the S&P 500, Nasdaq and Dow Jones added around 2.5, 2.7 and 2.6 per cent, respectively, on Tuesday. Specialty chemicals producer Croda International led the FTSE 100 on Wednesday with a 10.5 per cent climb, but most of the top ten performers were either banks or mining giants. Antofagasta was 6.8 per cent higher, while Anglo American was 6.7 per cent up, and Asia-focused Standard Chartered had risen 5.9 per cent. Reprieve for Powell Trump said he was not planning to sack Jerome Powell, the Fed's boss, who he has repeatedly criticised for not cutting interest rates fast enough. The US President rattled global markets on Monday when he called Powell 'a major loser' on his Truth Social account, but he told reporters at the White House yesterday that he had 'no intention' of firing the Fed chair. 'I would like to see him be a little more active in terms of his idea to lower interest rates,' he added. 'This is the perfect time to lower interest rates. If he doesn't, is it the end? No, it's not.' Markets were also boosted following US Treasury Secretary Scott Bessent's remarks that a trade war with China was 'unsustainable'. In a speech at an investors' conference hosted by JP Morgan, the former hedge fund manager said he expected a 'de-escalation' in the trade war between the US and China. According to a transcript obtained by the Associated Press, Bessent told investors: 'I do say China is going to be a slog in terms of the negotiations. Neither side thinks the status quo is sustainable.' The S&P 500 reacted strongly to the comments, ending Tuesday 2.5 per cent higher, while the Dow and Nasdaq achieved gains of about 2.7 per cent each. Asian markets also did well in the wake of Trump and Bessent's words, with the Hang Seng growing 2.4 per cent, the Nikkei up 1.9 per cent and South Korea's Kospi 1.6 per cent higher. How have markets fared since Trump's 'Liberation Day'? Susannah Streeter, head of money and markets at Hargreaves Lansdown, remarked: 'Financial markets are adjusting to Trump's modus operandi, which is to speak and act impulsively, and then retract some moves later. 'Just how much of the damage will linger remains to be seen, and markets are likely to stay volatile as trade negotiations play out.' By comparison, spot gold prices slumped from their record high of $3,500 per ounce on Tuesday by about 5 per cent to $3,334.83/oz. Investors have increasingly flocked to gold recently as Trump's on-again, off-again tariffs have incited massive turmoil in global markets. The US Government currently imposes a baseline tariff of 10 per cent on all imported goods, a 25 per cent tax on steel and aluminium products entering the US, and a whopping 145 per cent tariff on Chinese goods. Russ Mould, investment director at AJ Bell, said Trump and Bessent's comments 'have given markets a sense of optimism that recent chaos might have peaked and we're heading towards calmer waters. 'It almost suggests that someone has taken Trump to one side and told him it's time to be more responsible with his words and actions.' Stock markets still remain below their levels on 'Liberation Day' - 2 April - when Trump announced his sweeping tariff measures, according to AJ Bell data. The S&P 500 is down 6.7 per cent, while the FTSE 100 is 1.8 per cent lower.
Yahoo
20-04-2025
- Business
- Yahoo
Here's 5-stock ISA portfolio that could generate £1,000 per year in passive income
The dividend tax threshold has been coming down over the last few years. But for those who can avoid this by using an ISA, £20,000 can generate a lot of passive income. With interest rates at 4.5%, it might be tempting to look for income outside the stock market. Over the long term, however, I think UK investors stand to do better with dividend shares. Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions. I always look to invest in the best opportunities I can find, regardless of which exchange they're listed on. But with dividends, there are advantages to focusing on UK shares. The most obvious is tax – distributions from companies outside the UK are subject to withholding taxes. In the case of the US, this is 30%. That can be reduced to 15% with a W-8BEN form, but that's still enough to turn a 4% dividend yield into a 3.4% dividend yield. And investors have to factor this into their calculations. If a US company is good (or cheap) enough, it could absolutely offset this cost. But UK shares have an immediate advantage for investors looking for passive income in an ISA. Investing £20,000 to earn £1,000 per year implies a 5% dividend yield. And with UK shares prices where they are, I think that's highly achievable. An example portfolio could look like this: Stock Dividend yield Admiral 5.30% Croda International 4.20% Diageo 3.9% Primary Health Properties 7.20% Tesco 4.40% Investing £4,000 into each of these stocks could generate £1,000 per year in dividends. And there's always the option to reinvest those dividends to earn more income in the future. The stock with the highest dividend yield is Primary Health Properties (LSE:PHP). In general, I'm wary of stocks with unusually high yields, but this one is a rare exception. Primary Health Properties is a FTSE 250-listed real estate investment trust (REIT). It makes money by owning and leasing GP surgeries throughout the UK (and a bit in Ireland). As a REIT, the company has to distribute 90% of its rental income to investors in the form of dividends. And with most of its rent coming from the government, it's been very reliable. One thing real estate companies want to avoid is vacancies, but demand for GP surgeries has generally been strong. And people living longer means this could well be a durable trend. I think growth is likely to be steady, rather than spectacular. But with a dividend yield of 7.2% investors might well feel there's enough to generate a good return without big increases. Given this, a natural question is why not just buy Primary Health Properties and forget about the other stocks? The answer is that – as with all shares – there are risks with the business. The biggest potential issue is the fact the firm's debt is higher than its market value. So if it has to pay this off, the dividend per share could fall significantly. Even if this happens, I don't think the stock will turn out to be a terrible investment. But it's why investors should consider it as part of a diversified portfolio, rather than by itself. The post Here's 5-stock ISA portfolio that could generate £1,000 per year in passive income appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Stephen Wright has positions in Diageo Plc. The Motley Fool UK has recommended Admiral Group Plc, Croda International Plc, Diageo Plc, Primary Health Properties Plc, and Tesco Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Yahoo
15-03-2025
- Business
- Yahoo
Croda International Full Year 2024 Earnings: EPS Misses Expectations
Revenue: UK£1.63b (down 3.9% from FY 2023). Net income: UK£158.5m (down 7.3% from FY 2023). Profit margin: 9.7% (in line with FY 2023). EPS: UK£1.14 (down from UK£1.23 in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.7%. The primary driver behind last 12 months revenue was the Consumer Care segment contributing a total revenue of UK£920.0m (57% of total revenue). Notably, cost of sales worth UK£894.2m amounted to 55% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to UK£422.8m (73% of total expenses). Explore how CRDA's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 3.9% decline forecast for the Chemicals industry in the United Kingdom. Performance of the British Chemicals industry. The company's shares are down 4.5% from a week ago. Before we wrap up, we've discovered 1 warning sign for Croda International that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
